Revolution Medicines (RVMD) news

Revolution Medicines, Inc.: Needham raises target price to $275 from $240

On August 31, 2026, UBS raised its price target for Revolution Medicines, Inc. (NASDAQ: RVMD) to $265 from $220, while Guggenheim increased its target to $275 from $240. These adjustments reflect ongoing analyst optimism about the company’s long-term prospects, despite recent financial challenges.…

Revolution Medicines, Inc.: Wedbush raises target price to $225 from $201

Revolution Medicines, Inc.: H.C. Wainwright raises target price to $280 from $195

H.C. Wainwright has revised its price target for Revolution Medicines, Inc. (NASDAQ: RVMD) to $280 per share, up from the previous target of $195. The adjustment reflects the firm’s updated assessment of the company’s financial outlook and market positioning. The new target suggests increased…

Revolution Medicines - Rasonque is now commercially available in the U.S. at a wholesale acquisition cost of $39,800 for a 30-day supply - Conf call

Revolution Medicines has announced that Rasonque, its newly approved targeted therapy for pancreatic cancer, is now commercially available in the United States. The drug, which received FDA approval following the successful Phase 3 RASolute 302 trial, carries a wholesale acquisition cost (WAC) of…

Revolution Medicines shares up 1% after US FDA approves pancreatic cancer drug

Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic PDAC . The NDA is…